Calamos Advisors LLC Makes New $2.54 Million Investment in 10x Genomics $TXG

Key Points

• Calamos Advisors opened a new 10x Genomics position in the third quarter, buying 28,116 shares worth about $2.54 million. Several other institutional investors also initiated positions; institutions collectively own 84.68% of the stock.
• 10x Genomics’ latest quarterly results beat estimates, with a loss of $0.15 per share versus the expected $0.27 loss and revenue of $150.67 million versus $147.96 million expected. Revenue grew 1.1% year over year, but the company remained unprofitable.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $68.07. UBS lowered its target to $61, while Barclays raised its target to $110.

Calamos Advisors LLC bought a new position in shares of 10x Genomics (NASDAQ:TXG - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 28,116 shares of the company's stock, valued at approximately $2,541,000.

Other institutional investors have also recently made changes to their positions in the company. MBA Advisors LLC purchased a new position in shares of 10x Genomics in the third quarter valued at $277,000. Greenleaf Trust purchased a new stake in 10x Genomics during the 3rd quarter worth about $330,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in 10x Genomics during the 3rd quarter worth about $4,491,000. Profund Advisors LLC purchased a new stake in 10x Genomics during the 3rd quarter worth about $209,000. Finally, MGO One Seven LLC bought a new position in 10x Genomics in the 3rd quarter worth about $307,000. Hedge funds and other institutional investors own 84.68% of the company's stock.

10x Genomics Stock Performance

10x Genomics stock opened at $59.28 on Monday. 10x Genomics has a fifty-two week low of $13.58 and a fifty-two week high of $102.81. The stock has a market cap of $7.72 billion, a P/E ratio of -114.00 and a beta of 2.03. The firm's fifty day moving average price is $73.95 and its 200-day moving average price is $41.59.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.12. 10x Genomics had a negative return on equity of 8.26% and a negative net margin of 10.84%. The company had revenue of $150.67 million during the quarter, compared to analyst estimates of $147.96 million. During the same quarter last year, the company earned ($0.22) earnings per share. The firm's quarterly revenue was up 1.1% on a year-over-year basis. Sell-side analysts predict that 10x Genomics will post -0.77 earnings per share for the current year.

Insider Transactions at 10x Genomics

In related news, CFO Adam Taich sold 46,388 shares of the company's stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $64.57, for a total value of $2,995,273.16. Following the transaction, the chief financial officer directly owned 316,344 shares in the company, valued at approximately $20,426,332.08. This represents a 12.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 13,818 shares of the company's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $63.02, for a total transaction of $870,810.36. Following the completion of the transaction, the insider owned 488,182 shares in the company, valued at approximately $30,765,229.64. This trade represents a 2.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 179,333 shares of company stock worth $11,810,070. 8.84% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Royal Bank Of Canada started coverage on 10x Genomics in a report on Tuesday, September 1st. They set a "sector perform" rating and a $70.00 target price for the company. UBS Group lowered their price target on shares of 10x Genomics from $90.00 to $61.00 and set a "neutral" rating on the stock in a report on Friday. Piper Sandler increased their price target on shares of 10x Genomics from $47.00 to $80.00 and gave the stock a "neutral" rating in a report on Monday, September 28th. Barclays raised their price objective on shares of 10x Genomics from $52.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. Finally, Stephens cut shares of 10x Genomics from an "overweight" rating to an "equal weight" rating in a research note on Friday, October 23rd. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, 10x Genomics currently has a consensus rating of "Hold" and a consensus target price of $68.07.

10x Genomics News Roundup

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ expectations, while revenue of $150.7 million topped estimates. The company also raised its 2026 revenue outlook to $625 million–$635 million, above the roughly $620 million consensus. Q3 results
• Positive Sentiment: The company launched Sentira Single Cell, an AI-powered tool intended to simplify cell-data analysis. The product could support research adoption and create recurring revenue opportunities. Sentira launch
• Neutral Sentiment: Citigroup raised its price target from $50 to $60 but kept a neutral rating, suggesting limited upside at the cited share price. Citi target update
• Negative Sentiment: UBS cut its target from $90 to $61 and maintained a neutral rating. Meanwhile, Q3 revenue grew just 1.1% year over year and the company remains loss-making; management also cited production constraints and margin pressure, tempering optimism around stronger Atera demand. UBS target update Q3 call highlights

10x Genomics Profile

10x Genomics, Inc develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue.

The company's product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves research and clinical customers around the world, including academic institutions, biotechnology and pharmaceutical companies, and other research organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.